Cancer of Prostate Clinical Trial
Official title:
Real-time Motion Management During Prostate and Lung Radiotherapy
The goal of this interventional non-inferiority trial is to assess the accuracy of different real-time motion management radiotherapy techniques. The main question the study aims to answer are: - What are the target margins for radiotherapy with motion management that are not inferior to target margin without motion management - What are the dosimetric and geometrical accuracy to patient for the motion management techniques. Participants will answer QoL questionary, and the accuracy of treatment will be assessed from treatment data.
This study will assess the feasibility of implementing real-time tracking in a clinical setting to account for the relative motion of the moving tumours localised to the prostate or lung. The capability to track the treatment target's motion will ensure that the dose prescribed by the radiation oncologist is the dose delivered to the target and minimises side effects to the critical organs. During radiation treatment, the target position will be monitored in real-time using built-in imaging technology. The radiation beam shape will be altered to compensate for the moved target positions by the treatment delivery system. The delivered dose to the patient will be calculated after the treatment and compared to the dose without real-time tracking to assess the potential benefit to treatment efficacy, recognising that the radiation dose received by tumour tissue is a very strong biomarker for response. The estimated dose distributions will be compared to the original plan for non-inferiority using the dose reconstruction method based on the prostate motion trajectory and the logged MLC positions (beam shapes). Also, the impact on organs at risk doses due to MLC target tracking. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT05191017 -
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
|
Phase 1/Phase 2 | |
| Completed |
NCT00970203 -
Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer
|
Phase 2 | |
| Completed |
NCT03031418 -
Clinical Evaluation of the 'ExoDx Prostate IntelliScore' (EPI)
|
||
| Completed |
NCT01639859 -
Assessment of Supersonic Imagine Aixplorer for the Detection and Localisation of Prostate Cancer Foci
|
N/A | |
| Completed |
NCT02362464 -
Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139
|
Phase 2 | |
| Completed |
NCT03442075 -
Pain Comparison Whit Visual Analog Scale (EVA) Between Four Analgesic Methods During Trans Rectal Prostatic Biopsy
|
||
| Recruiting |
NCT05252390 -
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03896958 -
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
|
||
| Completed |
NCT03444532 -
Feasibility Study Testing a Sleep Intervention in Prostate Cancer Patients With Insomnia
|
N/A | |
| Recruiting |
NCT05600400 -
Improving Sexual Quality of Life - Randomized Trial of Two vs Five MRI Guided SABR Treatments for Prostate Cancer
|
N/A | |
| Not yet recruiting |
NCT05653063 -
ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate Cancer
|
||
| Completed |
NCT02235142 -
Prostatic Cancer Versus Androgen Deficiency
|
N/A | |
| Recruiting |
NCT06318559 -
Artificial Intelligence 3D Augmented Reality Robot-Assisted-Radical- Prostatectomy v.s. no3D Intervention
|
N/A | |
| Completed |
NCT01477749 -
Sipuleucel-T Manufacturing Demonstration Study
|
Phase 2 | |
| Active, not recruiting |
NCT03632980 -
Dynamic Focusing Evaluation for Prostate Cancer Treatment
|
N/A | |
| Recruiting |
NCT04319783 -
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA
|
Phase 2 | |
| Recruiting |
NCT04258813 -
Onco-primary Care Networking to Support TEAM-based Care
|
N/A | |
| Recruiting |
NCT05361798 -
T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy
|
Phase 2 | |
| Completed |
NCT04304196 -
Tailored, wEb-based, Psychosocial and Physical Activity Self-Management PrOgramme
|
N/A | |
| Completed |
NCT02564120 -
North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS)
|